Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33,272Revenue $M1,551Net Margin (%)20.9Z-Score31.8
Enterprise Value $M31,819EPS $1.3Operating Margin %36.5F-Score6
P/E(ttm))84.4Cash Flow Per Share $0.8Pre-tax Margin (%)36.6Higher ROA y-yN
Price/Book11.510-y EBITDA Growth Rate %0Quick Ratio5.3Cash flow > EarningsY
Price/Sales17.75-y EBITDA Growth Rate %52.4Current Ratio5.6Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %38.3ROA % (ttm)12.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)16.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M198ROI % (ttm)16.0Gross Margin Increase y-yN

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNAndreas Halvorsen 2014-06-30 Add0.12%$139.61 - $170.2
($157.93)
$ 168.26%Add 9.23%2,006,092
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 168.26%Add 240.11%17,094
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 168.26%Reduce -47.72%26,332
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 168.26%Sold Out0
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 168.26%New holding, 50371 sh.50,371
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 168.26%New holding, 5026 sh.5,026
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 168.26%New holding, 1318 sh.1,318
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 168.26%New holding, 10218 sh.10,218
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 168.26%Reduce -28.52%5,268,418
ALXNAndreas Halvorsen 2014-03-31 Reduce-0.65%$129.82 - $183.89
($158.27)
$ 168.26%Reduce -36.16%1,836,658
ALXNAndreas Halvorsen 2013-12-31 Reduce-0.37%$105.48 - $132.91
($119.84)
$ 168.240%Reduce -16.72%2,877,008
ALXNAndreas Halvorsen 2013-09-30 Reduce-1.06%$94.34 - $117.28
($109.83)
$ 168.253%Reduce -37.7%3,454,640
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 168.253%Reduce -10.5%7,540,405
ALXNAndreas Halvorsen 2013-06-30 Reduce-2.15%$87.99 - $107.86
($96.37)
$ 168.274%Reduce -41.4%5,544,949
ALXNAndreas Halvorsen 2013-03-31 Add2.99%$83.39 - $102.57
($93.13)
$ 168.281%Add 135.72%9,462,442
ALXNFrank Sands 2013-03-31 Add0.11%$83.39 - $102.57
($93.13)
$ 168.281%Add 4.23%8,420,336
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 168.281%Sold Out0
ALXNAndreas Halvorsen 2012-12-31 Buy 2.6%$87.97 - $118.15
($98.27)
$ 168.271%New holding, 4014242 sh.4,014,242
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 168.271%New holding, 12977 sh.12,977
ALXNFrank Sands 2012-06-30 Add0.27%$83.74 - $98.82
($91.04)
$ 168.285%Add 6.43%9,739,804
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN Joel Greenblatt 2014-06-3017,0940.010.03+240.11%
ALXN Andreas Halvorsen 2014-06-302,006,0921.011.4+9.23%
ALXN Frank Sands 2014-06-305,279,7822.672.1+0.22%
ALXN Ron Baron 2014-06-3010,1450.010.01-0.71%
ALXN Ray Dalio 2014-06-3026,3320.010.03-47.72%
ALXN John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Moriarty John BSVP & General Counsel 2014-10-06Sell10,000$179-6.03view
SQUINTO STEPHEN PEVP, Chief Global Ops. Officer 2014-10-03Sell10,025$172.41-2.44view
BELL LEONARDCEO 2014-09-26Sell60,000$165.121.87view
SQUINTO STEPHEN PEVP, Chief Global Ops. Officer 2014-09-24Sell76$159.55.45view
BELL LEONARDCEO 2014-09-18Sell44,435$160.64.73view
BELL LEONARDCEO 2014-09-10Sell12,199$165.381.71view
BELL LEONARDCEO 2014-09-08Sell197,801$165.321.74view
Carmichael ClareSVP, Chief HR Officer 2014-09-02Sell304$169.46-0.74view
BELL LEONARDCEO 2014-08-27Sell5,912$169.17-0.57view
Rummelt AndreasDirector 2014-08-25Sell5,052$170.53-1.37view

Press Releases about ALXN :

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
fv 107 Apr 01 2013 
Weekly Top Insider Sells: GOOG, KSS, ALXN, and QCOM Sep 03 2012 

More From Our Partners
Markets Rebound After Getting Crushed Intraday, Still Close Lower Oct 15 2014 - BENZINGA

More From Other Websites
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings Oct 20 2014
Celgene, Alexion Among 4 IBD 50 Medicals To Report Oct 18 2014
Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa Oct 16 2014
Analyst Top Biotech Stocks Could Explode After Huge Sell-Off Oct 16 2014
Markets Rebound After Getting Crushed Intraday, Still Close Lower Oct 15 2014
Alexion Eyes European Headquarters in Zurich on Expansion Push Oct 15 2014
Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Oct 15 2014
Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Oct 15 2014
Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Oct 15 2014
Stocks Close Mixed, Surrendering Some Early Gains Oct 14 2014
Alexion Pharmaceuticals to Report Third Quarter 2014 Results on Thursday, October 23, 2014 Oct 09 2014
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Oct 09 2014
Alexion Board of Directors Appoints New Chairman and Creates the New Position of Lead Independent... Oct 09 2014
Three Leading Medicals Staying Healthy In Correction Oct 08 2014
Video: 3 Big Cap Biotechs Bucking Market Correction Oct 08 2014
Stocks Soar After Fed Minutes; Leaders Reverse Higher Oct 08 2014
Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update Oct 08 2014
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Oct 07 2014
Alexion Announces the Passing of Max Link, Ph.D., Chairman of the Company’s Board of Directors Oct 07 2014
Better-than-expected jobs data helped benchmarks end in the green on Friday Oct 06 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK